Dec. 31 Deadline Looms For Dozens Of Unlicensed Medical Marijuana Firms In Michigan

Up to six dozen unlicensed medical cannabis businesses in Michigan must close at least temporarily by Dec. 31 or risk not receiving a permanent license under a new, stricter regulatory system, state officials indicated Friday.

Regulators noted in a news release that Michigan Court of Claims Judge Stephen Borrello had dismissed the last pending court case challenging the state’s deadline.

State officials previously had agreed that businesses that had applied for a license under the new regulatory system by Feb. 15 and had local approval could temporarily operate until Dec. 31.

David Harns, spokesman for the Michigan Department of Licensing and Regulatory Affairs, wouldn’t say if the state would actively enforce the Dec. 31 deadline.

He would say that “it is very important for temporarily operating applicants to understand that any operation after Monday may be considered an impediment to licensure.”

Harns wrote in an email that up to 72 businesses might be affected, “though we don’t truly know if all 72 are currently open.”

Michigan regulators have approved 99 licenses under the new system, including 52 dispensaries. The next meeting to consider license applications is Jan. 16.

Advocates had been concerned about possible supply and access issues during the transition to the new, trimmed-down system. The state once had several hundred dispensaries, although that number was cut roughly in half earlier this year.

To ease supply concerns, Michigan regulators are allowing licensed MMJ businesses to supplement their supplies by buying products from registered caregivers through Dec. 31 and selling those products until Jan. 31, 2019.

Original Article Source: https://mjbizdaily.com/unlicensed-medical-marijuana-businesses-michigan-face-dec-31-deadline/

Comments

Could CBD Lead To The Development Of Safer Antipsychotic Medications?

Antipsychotic medications are important for managing a number of different psychiatric ailments, including bipolar disorders, schizophrenia, and even dementia. These drugs can greatly improve the manageability of symptoms that often distort one’s experience of reality. They can also create major mood disruptions and lead to a number of behavioral and emotional difficulties. Antipsychotic and anti-psychosis medications can be life-changing for people with such disorders, enabling them to live more normal and manageable lives without their symptoms taking over. These drugs work by regulating neurotransmitters in the brain so that naturally occurring imbalances and dysfunctions no longer disrupt mental and emotional processes. Often, reaching this outcome is much easier said than done; it can take a lot of time to find courses and combinations of treatments that work. It’s sometimes necessary to make adjustments to find the right balance for the individual and it’s not unusual for outc...

Cannabis Watch: Canopy Growth To Book Charge Of Up To $568 Million As Marijuana Restructuring Continues

Canopy Growth Corp. said early Thursday it was halting a range of operations across three continents and expects its restructuring plans to result in a charge of up to C$800 million (567.9 million) in the fiscal fourth quarter. U.S.-traded shares US:CGC CA:WEED of the cannabis company fell 1.9% in afternoon trading. Canopy said it was selling operations in Africa, curtailing cultivation of hemp in the U.S. and Columbia, and shutting down an indoor production facility in Canada. The announcement will result in 85 job cuts, the company said. “When I arrived at Canopy Growth in January, I committed to conducting a strategic review in order to lower our cost structure and reduce our cash burn,” Canopy Chief Executive David Klein said in a statement. Read: As cannabis industry stays largely quiet on coronavirus, this CEO has been sounding the alarm Canopy’s restructuring announcement was expected by investors, Cowen analyst Vivien Azer wrote in a note to clients Thursday. Azer rate...

Can Medical Marijuana Help Aging Parents With Dementia?

For decades, marijuana, even for medical uses, was demonized or questioned. When states like Colorado legalized it for recreational use, more studies began to determine provable efficacy for its use as a medicine. The Federal government still classifies marijuana the same way it classifies heroin: harmful and with no medical benefits. Now we can see that this is wrong. When states legalized marijuana, referred to as cannabis here, they had an interest in getting data to see what good it could do. Proving efficacy could increase medical marijuana sales, benefit people who might at least find some medical use, and overall would bring tax dollars into the state coffers. Without funding studies, the Federal government has done very little to demonstrate what good cannabis can do. After all, if the presumption is that it helps nothing, there would be no motivation to determine with scientific data that it does anyone any good. But we have convincing data now about its beneficial use ...

Norma Pence

Search This Blog